0001140361-26-019336
SEC filingExceptional profitability surge with gross profit up 32% to $80.8M and net income up 68% to $45.3M despite flat revenue, driven by substantial operating income gains from yield enhancements and ASCENIV growth offsetting BIVIGAM volume declines.
Operating income more than doubled, up 67% to $58.3M at 50.9% of revenue, with the improvement primarily due to the substantial gross profit increase. Investors benefit from this leverage as fixed cost structures amplify margin gains into bottom-line expansion, funding growth without dilution.
These dynamics affirm management's focus on production efficiency amid rising input costs like consumables, utilities, freight, and labor. Boca Facility enhancements enhance supply chain resilience, while ASCENIV's rapid growth trajectory continues. Pipeline investments in SG-001 development signal upside, though FDA licensing timelines for plasma centers remain a risk to production plans. Liquidity extends through 2027, supporting sustained execution.